MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy
…, MW Konijnenberg, RG Dale, HB Breitz… - Journal of Nuclear …, 2008 - Soc Nuclear Med
Renal toxicity associated with small-molecule radionuclide therapy has been shown to be
dose-limiting for many clinical studies. Strategies for maximizing dose to the target tissues …
dose-limiting for many clinical studies. Strategies for maximizing dose to the target tissues …
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
…, M Tempero, PL Weiden, L Gentner, H Breitz… - Clinical Cancer …, 2000 - AACR
A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin ( 90 Y-DOTA-biotin)
pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary …
pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary …
[PDF][PDF] Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin
HB Breitz, PL Weiden, PL Beaumier… - Journal of Nuclear …, 2000 - Soc Nuclear Med
Pretargeted radioimmunotherapy (PRIT) was evaluated using an antibody-streptavidinconjugate,
followed by a biotin-galactose humanserumalbuminclearingagentand@ ÂY-…
followed by a biotin-galactose humanserumalbuminclearingagentand@ ÂY-…
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
…, ML Goris, VJ Picozzi, DB Axworthy, HB Breitz… - Blood, 2004 - ashpublications.org
Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide
delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 …
delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 …
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials
…, D Maloney, L Holmberg, J Rajandran, H Breitz… - Blood, 2003 - ashpublications.org
Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-tetramethylenephosphonate ( 166
Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver …
Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver …
[PDF][PDF] Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry
MG Stabin, HB Breitz - Journal of Nuclear Medicine, 2000 - Soc Nuclear Med
There is substantial variation of the normal anatomy of the breast among individuals and within
an individual at different stages of life. Specific changes occur with puberty, the menstrual …
an individual at different stages of life. Specific changes occur with puberty, the menstrual …
Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results
PL Weiden, HB Breitz, O Press… - Cancer biotherapy & …, 2000 - liebertpub.com
Pretargeted radioimmunotherapy (PRIT™) was investigated in patients with non-Hodgkin's
lymphoma (NHL). The PRIT approach used in this study is a multi-step delivery system in …
lymphoma (NHL). The PRIT approach used in this study is a multi-step delivery system in …
[PDF][PDF] Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer
…, FR MacKintosh, DA Karlin, GS Baker, HB Breitz - J Clin …, 2009 - researchgate.net
… Baker, and Hazel B. Breitz … Breitz, Poniard Pharmaceuticals (C) Consultant or Advisory
Role: John R. Eckardt, Poniard Pharmaceuticals (C) Stock Ownership: None Honoraria …
Role: John R. Eckardt, Poniard Pharmaceuticals (C) Stock Ownership: None Honoraria …
[PDF][PDF] Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials
HB Breitz, PL Weiden, JL Vanderheyden… - Journal of Nuclear …, 1992 - Soc Nuclear Med
Therapy (no. of pts): None or antimetabo 6 17lites onlyRadiation ±antime 3 6tabolitesIntensive
chemo ±6 8radiation and MTD of) ssRe@ labeledintact NR-LU-10, and 186Re labeled …
chemo ±6 8radiation and MTD of) ssRe@ labeledintact NR-LU-10, and 186Re labeled …
Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
PL Weiden, HB Breitz - Critical reviews in oncology/hematology, 2001 - Elsevier
Pretargeted radioimmunotherapy (PRIT™) was first investigated in a series of phase I and
phase II studies in patients with adenocarcinoma using a pancarcinoma antibody, NR-LU-10. …
phase II studies in patients with adenocarcinoma using a pancarcinoma antibody, NR-LU-10. …